Olink Holding AB utilizes its proprietary Proximity Extension Assay technology to offer a high-multiplex technique for identifying biomarkers in the human plasma proteome. With minimal sample volume, Olink provides quantifiable results with high-throughput, sensitivity, and specificity, covering a broad dynamic range. The company is well-established in Europe and the USA, with a growing presence in Asia. Olink works with core labs worldwide to support a global customer base and continuously expands its protein coverage for various biological processes and pathways.